Monday 24 October 2011

Fungizone




In some countries, this medicine may only be approved for veterinary use.


In the US, Fungizone (amphotericin b systemic) is a member of the drug class polyenes and is used to treat Aspergillosis - Aspergilloma, Aspergillosis - Invasive, Blastomycosis, Candida Infections - Systemic, Candida Urinary Tract Infection, Coccidioidomycosis, Coccidioidomycosis - Meningitis, Cryptococcal Meningitis - Immunocompetent Host, Cryptococcal Meningitis - Immunosuppressed Host, Cryptococcosis, Esophageal Candidiasis, Fungal Endocarditis, Fungal Infection Prophylaxis, Histoplasmosis - Immunocompenent Host, Histoplasmosis - Meningitis, Leishmaniasis, Oral Thrush, Paracoccidioidomycosis and Sporotrichosis.

US matches:

  • Fungizone

  • Fungizone Cream

  • Fungizone For Tissue Culture

  • Fungizone Lotion

  • Fungizone Intravenous, Injection

  • Fungizone Topical

UK matches:

  • Fungizone 50mg Powder for Sterile Concentrate (SPC)

Ingredient matches for Fungizone



Amphotericin B

Amphotericin B is reported as an ingredient of Fungizone in the following countries:


  • Algeria

  • Australia

  • Belgium

  • Benin

  • Burkina Faso

  • Cameroon

  • Canada

  • Central African Republic

  • Chad

  • Congo

  • Cote D'ivoire

  • Denmark

  • Finland

  • France

  • Gabon

  • Greece

  • Guinea

  • Hong Kong

  • Hungary

  • Iceland

  • India

  • Indonesia

  • Ireland

  • Italy

  • Japan

  • Kenya

  • Luxembourg

  • Madagascar

  • Mali

  • Mauritania

  • Mauritius

  • Netherlands

  • New Zealand

  • Niger

  • Nigeria

  • Norway

  • Philippines

  • Senegal

  • Serbia

  • Singapore

  • South Africa

  • Sweden

  • Switzerland

  • Taiwan

  • Tanzania

  • Thailand

  • Togo

  • Tunisia

  • Turkey

  • Uganda

  • United Kingdom

  • United States

  • Venezuela

  • Zaire

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

No comments:

Post a Comment